Asymmetric dimethylarginine and gestational diabetes mellitus: a systematic review and meta-analysis
Date
2022
Authors
Tiong, P.
Kosmider, L.
Lassi, Z.S.
Arstall, M.A.
Andraweera, P.H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Endocrine, 2022; 80(2)
Statement of Responsibility
Patricia Tiong, Logan Kosmider, Zohra S. Lassi, Margaret A. Arstall, Prabha H. Andraweera
Conference Name
Abstract
PURPOSE: Emerging evidence demonstrates that asymmetric dimethylarginine (ADMA) levels are elevated in patients with or at risk of cardiovascular disease (CVD). Since women with gestational diabetes mellitus (GDM) are at high risk of future CVD, we conducted a systematic review and meta-analysis to compare ADMA concentrations between women with and without GDM during pregnancy and postpartum. METHODS: PubMed, Google Scholar, EMBASE, and CINAHL databases were searched. The review protocol is registered in PROSPERO (CRD42021276796). Study selection, data extraction, and data analyses were performed in accordance with PRISMA guidelines. Random-effects model was used to quantify ADMA levels in the study groups. RESULTS: Eleven studies provided data on 1148 women. Mean plasma ADMA concentration was 0.04 μmol/L (95% confidence interval (CI) -0.06-0.15) higher in pregnant women with GDM than those without GDM, but no significant difference was observed. In contrast, our meta-analysis demonstrated a significant increase in postpartum mean ADMA concentration (Mean Difference (MD) 0.11 μmol/L; 95% CI 0.05-0.16) among women with previous GDM compared to women without previous GDM. CONCLUSION: Elevated ADMA levels in GDM may be a CVD risk factor, suggesting that ADMA may be a potential biomarker for early CVD risk prediction in women with GDM.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022